- Record: found
- Abstract: not found
- Article: not found
Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies
November 2018
November 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the durability of diabetic retinopathy (DR) improvements after a change
in ranibizumab dosing from monthly to individualized pro re nata (PRN) therapy.